Approval was supported by the phase 3 LANDI-PED study, which demonstrated significant heart rate reduction and conversion to normal sinus rhythm in pediatric patients.
RAPIBLYK (R) is an ultra-short-acting, selective beta-1 adrenergic receptor blocker administered intravenously in a monitored hospital setting. Its pharmacological profile allows for rapid onset and ...
FDA approval for RAPIBLYK® (landiolol) for use in pediatric patients with SVT provides first therapeutic option for these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results